Liver function tests and one year risperidone treatment in children and adolescents

2011 ◽  
Vol 26 (S2) ◽  
pp. 280-280
Author(s):  
A. Erdogan ◽  
N. Yurteri ◽  
A.E. Tufan ◽  
H. Ankarali ◽  
E. Demirci
Keyword(s):  
Liver Function ◽  
Children And Adolescents ◽  
Liver Enzymes ◽  
Antipsychotic Agent ◽  
Liver Function Tests ◽  
Function Tests ◽  
The Mean ◽  
One Year ◽  
Risperidone Treatment

ObjectiveRisperidone is an atypical antipsychotic agent, despite its many advantages and widespread use, there is increasing attention to the adverse effects associated with long-term exposure to this drug.We aimed to investigate the changes in the liver function tests (LFTs) associated with one year risperidone treatment in children and adolescents.MethodsOne hundred youths who treated with risperidone more than one year were included in the study. For this study, patients’ baseline and follow-up weight and hepatobiliary function tests including alanine aminotransferases(ALT) and aspartat aminotransferases (AST), gamma gluatamyl transerase (GGT), alkaline phosphatase (ALP) and serum bilirubin levels were measured baseline, after the treatment period of six months and one year.ResultsAsymptomatic liver function test abnormalities mostly ALP elevation was found in subjects treated with risperidone. The mean levels of liver enzymes and billuribin of the patients were significantly higher after one year of treatment than the baseline. Also the mean levels of liver enzymes and billuribin of the patients were significantly higher after one year of treatment than the six months. There was significant association between changes in weight, risperidone dose and liver enzymes and billuribin levels.ConclusionsThese findings suggest that risperidone treatment in the long term commonly leads to liver function changes however it rarely may induce a serious hepatic toxicity at therapeutic doses in children and adolescents.

scholarly journals Liver function tests in patients of pre-eclampsia in Bhilai, Chhattisgarh, India: a clinical study

2018 ◽  
Vol 7 (12) ◽  
pp. 5102
Author(s):  
Rashid Lodhi ◽  
Navanil Roy
Keyword(s):  
Blood Pressure ◽  
Liver Function ◽  
Pregnant Women ◽  
Total Protein ◽  
Liver Enzymes ◽  
Serum Bilirubin ◽  
Liver Function Tests ◽  
Mean Value ◽  
Function Tests ◽  
The Mean

Background: Pre-eclampsia is a multisystem disorder, which occurs only in pregnant women during the second and third trimesters of pregnancy and is associated with raised blood pressure and proteinuria. Liver function Test (LFT) abnormalities occur in 3% of the pregnancies and probably the lesion that causes elevated serum liver enzymes. This study was conducted to compare the liver function tests in pre-eclampsia with normal pregnancy.Methods: This study was carried out on 60 pregnant women after 20 weeks of gestation admitted in Obstetrics and Gynaecology units of Shri Shankaracharya Institute of Medical Sciences, Bhilai, and Chhattisgarh. The subjects were divided into two groups. Group A comprised of 30 cases of pre-eclampsia having blood pressure ≥ 140/90mm Hg, proteinuria in 24 hours ≥ 300 mg and edema.  Group B had 30 normal pregnant women after 20 weeks of gestation. The data including parity, period of gestation, blood pressure and presenting complaints of all subjects were recorded. Serum bilirubin, total protein, albumin and plasma levels of liver enzymes ALT and AST were measured.Results: The mean value of serum bilirubin in cases was 3.45 and in controls it was 0.50. The mean value of enzymes ALT in cases was 92.7 while in the controls it was 22.37. Mean serum AST in the cases was 85.43 and in the controls,  it was 21.96. Total protein in cases was 7.77 and controls it was 7.26. Albumin level in cases was 4.62 and controls were 4.17.Conclusions: Increased concentrations of serum bilirubin, total protein, albumin and liver enzymes ALT, AST were found in pre-eclampsia cases.

Liver-function tests in children and adolescents on antipsychotics: a one-year follow-up study

2016 ◽  
Vol 26 ◽  
pp. S734-S735
Author(s):  
I. Baeza Pertegaz ◽  
E. De la Serna ◽  
R. Calvo-Escalona ◽  
A. Morer ◽  
J. Merchán-Naranjo ◽  
...  
Keyword(s):  
Liver Function ◽  
Children And Adolescents ◽  
Liver Function Tests ◽  
Follow Up Study ◽  
Function Tests ◽  
One Year

scholarly journals Abnormal Liver Function Tests and Long-Term Outcomes in Patients Discharged after Acute Heart Failure

2021 ◽  
Vol 10 (8) ◽  
pp. 1730
Author(s):  
Hiroshi Miyama ◽  
Yasuyuki Shiraishi ◽  
Shun Kohsaka ◽  
Ayumi Goda ◽  
Yosuke Nishihata ◽  
...  
Keyword(s):  
Heart Failure ◽  
Liver Function ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Adverse Outcomes ◽  
Long Term Outcomes ◽  
Function Tests ◽  
Parameter Values

Abnormal liver function tests (LFTs) are known to be associated with impaired clinical outcomes in heart failure (HF) patients. However, this implication varies with each single LFT panel. We aim to evaluate the long-term outcomes of acute HF (AHF) patients by assessing multiple LFT panels in combination. From a prospective multicenter registry in Japan, 1158 AHF patients who were successfully discharged were analyzed (mean age, 73.9 ± 13.5 years; men, 58%). LFTs (i.e., total bilirubin, aspartate aminotransferase or alanine aminotransferase, and alkaline phosphatase) at discharge were assessed; borderline and abnormal LFTs were defined as 1 and ≥2 parameter values above the normal range, respectively. The primary endpoint was composite of all-cause death or HF readmission. At the time of discharge, 28.7% and 8.6% of patients showed borderline and abnormal LFTs, respectively. There were 196 (16.9%) deaths and 298 (25.7%) HF readmissions during a median 12.4-month follow-up period. The abnormal LFTs group had a significantly higher risk of experiencing the composite outcome (adjusted hazard ratio: 1.51, 95% confidence interval: 1.08–2.12, p = 0.017), whereas the borderline LFTs group was not associated with higher risk of adverse events when referenced to the normal LFTs group. Among AHF patients, the combined elevation of ≥2 LFT panels at discharge was associated with long-term adverse outcomes.

scholarly journals Vegan Diet Advice Might Benefit Liver Enzymes in Nonalcoholic Fatty Liver Disease: an Open Observational Pilot Study

2021 ◽  
Author(s):  
Giuseppe Chiarioni ◽  
Stefan Lucian Popa ◽  
Andrea Dalbeni ◽  
Carlo Senore ◽  
Daniel Corneliu Leucuta ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Liver Disease ◽  
Liver Function ◽  
Fatty Liver Disease ◽  
Liver Enzymes ◽  
Liver Function Tests ◽  
Vegan Diet ◽  
Nonalcoholic Fatty Liver ◽  
Function Tests

Background and Aims: The Western diet is rich in saturated fats, refined sugars and meat consistent with a high-energy load and secondary risk of increased metabolic diseases including nonalcoholic fatty liver disease (NAFLD). However, no data are available on potential benefit of vegan diets in NAFLD and/or nonalcoholic steatohepatitis (NASH). We aimed to study prospectively the effect of a vegan diet, excluding all animal products on liver chemistry in a group of consecutive NAFLD patients. Methods: This was a prospective, pilot study run on 40 consecutive patients affected by NAFLD. Eight subjects refused to join the study for poor diet palatability, leaving 32 patients (19 males, mean age 50 years), with abnormal measures of liver function who agreed to adhere to a vegan diet for six months. The caloric intake was tailored by the dietitian to obtain a weight loss ≥5% of body weight in overweight patients [body-mass index (BMI) ≥25] and ranged from 1500 Kcal to 1800 Kcal. Patients were contacted monthly by phone to reinforce diet and lifestyle advice and were seen at the gastrointestinal clinic when doubtful about diet advice. Results: At six-month follow-up, 6 subjects did not attend the clinic leaving only 26 patients for data analysis. Initial anthropometric values were mean weight 78 kg (range 52-95), mean body mass index (BMI) 26.8 Kg/m2 (range 20.3-31.2). Liver function tests showed mean ALT value 99 U/L (SD±45), mean AST value 54 U/L (SD±44), mean GGT value 160 U/L (SD±122), pre-treatment. After six months mean body weight was 73 Kg (range 52-87), mean BMI was 25.2 Kg/m2 (range 20.3-29.7) (p<0.001 compared to baseline for both parameters). Liver enzymes improved to a mean of ALT value 36 U/L (SD±21), AST value 27 U/L (SD±10) and GGT value 55 U/L (SD±57), respectively (p<0.001 compared to baseline for all enzymes). Normalization of liver function tests as a whole was observed in 20/26 patients (76.9%). A loss of ≥ 5% of body weight was observed in 12 patients (46.1%), but it did not correlate with the normalization of liver function tests (p=0.5). Conclusions: Our data provide preliminary evidence of improved liver enzymes in NAFLD patients with a strict vegan diet and although our study sample is limited, decreased body weight did not seem critical to the outcome.

Long-term effect of nadolol on quantitative liver function tests in patients with cirrhosis

1988 ◽  
Vol 34 (5) ◽  
pp. 501-504 ◽  
Author(s):  
C. Merkel ◽  
A. Gatta ◽  
D. Sacerdoti ◽  
M. Bolognesi ◽  
M. Rondana ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Function Tests ◽  
Term Effect ◽  
Function Tests ◽  
Long Term Effect

THE EFFECT OF LONG-TERM NEUROLEPTIC TREATMENT ON LIVER FUNCTION TESTS

1992 ◽  
Vol 15 ◽  
pp. 347B
Author(s):  
Nihat Alpay ◽  
Celal Ulaşolu ◽  
Yücel Aargün ◽  
Murat Huten
Keyword(s):  
Liver Function ◽  
Liver Function Tests ◽  
Neuroleptic Treatment ◽  
Function Tests
Sign in / Sign up

Export Citation Format

Share Document